Drugs / Leukocyte-Rich PRP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06524531 | Jul 2024 → Jul 2025 overdue | multiple organ dysfunction syndrome | Iffat Anwar Medical Complex | Recruiting | No outcome recorded |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT02923700 | Sep 2016 → Sep 2017 | osteoarthritis | Rizzoli Orthopaedic Institute | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leukocyte-Rich PRP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06524531 ↗ |
| Known as | LR-PRP | “PURPOSE: To compare the safety and effectiveness of leukocyte-rich PRP (LR-PRP) and leukocyte-poor PRP (LP-PRP) for the treatment of knee OA.” PMID 35103547 ↗ Feb 2022 |
| Route | Intramuscular | “injected into the multifidus muscle at the L2 and L3 levels” NCT06524531 ↗ |